Vaxcyte, Inc. (PCVX) Stock Price & Analysis

Vaxcyte, Inc. (PCVX) closed at USD 62.85 on Thursday, October 22, 2026, down 0.60% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 63.23; the Oct 22, 2026 session ranged USD 61.56–64.58 on volume of 2,771,276 shares. Market capitalization is $9.89B, with a 52-week range of USD 39.87–90.75 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:59 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PCVX.md

Key facts (PCVX)

• 1 of 80 tracked superinvestors hold PCVX (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (11 analysts), mean target USD 117.3 (range 75–163).
• Total return with dividends: 1Y +51.1% vs S&P 500 +14.9%; 5Y +176.8% vs S&P 500 +80.3%.
• Next earnings: 2026-11-03, EPS estimate USD -2.11, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PCVX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (PCVX)

P/B 3.6x · FCF yield -9.04% · Earnings yield -10.76%

Superinvestors (SEC 13F-HR, Q2 2026) (PCVX)

1 of 80 tracked investors hold PCVX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (PCVX)

Consensus Buy (mean 2.00 on a 1–5 scale), 11 analysts; mean target USD 117.3 (low 75, high 163).

Rating changes, last 120 days:

Total return (dividends reinvested) (PCVX)

PCVX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

Companies that name PCVX in their SEC reports

PCVX company outlook (results filed Aug 5, 2026)

• “EX-99.1 2 pcvx-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026;”
• “Topline Data Expected in Second Half of 2027 Approximately $2.5 Billion in Cash, Cash Equivalents and Investments as of June 30, 2026 SAN CARLOS, Calif., August 5, 2026 – Vaxcyte, Inc.”
• “Topline Data from OPUS-1 Expected in Fourth Quarter 2026: All three ongoing VAX-31 Phase 3 clinical trials (OPUS-1, OPUS-2 and OPUS-3) are fully enrolled with 6,191 adults dosed in total, approximately 3,500 of whom received VAX-31.”
• “The Stage 2 portion of the study is expected to proceed contingent upon the Data Safety Monitoring Board's approval following the review of unblinded Stage 1 safety and tolerability data.”

Quoted word-for-word from the SEC 8-K results press release.

PCVX analyst estimates and revisions

PCVX options: expected move

Options price a move of about ±12.0% (±$7.50) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±6.3% on average.

30-day implied volatility 53.6% vs 96.6% realized over the last 30 trading days. Put/call ratio (volume) 0.49. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:59 UTC)

Technical Analysis (PCVX)

Nexqual's technical model rates PCVX "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:59 UTC.

Analyst Ratings (PCVX)

Wall Street analysts rate PCVX "Buy" based on 11 analysts, with a mean price target of USD 117.3 (range USD 75–163), per Nexqual as of October 23, 2026 at 09:59 UTC.

Earnings (PCVX)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:59 UTC.

Financials & Fundamentals (PCVX)

Source: Nexqual, October 23, 2026 at 09:59 UTC.

Financial Health Score (PCVX)

Nexqual rates Vaxcyte, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:59 UTC.

Ownership (PCVX)

Source: Nexqual, October 23, 2026 at 09:59 UTC.

Leadership (PCVX)

Vaxcyte, Inc. is led by Grant E. Pickering, Co-Founder, CEO & Director, per Nexqual as of October 23, 2026 at 09:59 UTC.

Major Backers & Investors (PCVX)

Notable institutional backers of Vaxcyte, Inc. include FMR, LLC, Jupiter Topco LLC, T. Rowe Price, according to Nexqual as of October 23, 2026 at 09:59 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:59 UTC.

From Vaxcyte, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• The vaccines to prevent RSV from Pfizer and GSK that were approved by the FDA in May 2023, and from Moderna that was approved by the FDA in May 2024, generated approximately $1.8 billion in global sales in 2025.
• In that study, the OPA responses directed against the polysaccharides of interest for all thirteen of the common strains were lower for PCV20 (Figure 6). 1 IgG Geometric Mean Concentrations post-dose 4 – Prevnar 20 Biologics License Application ("BLA") Clinical Review Memorandum by FDA (STN: 125731/189).
• In contrast, the precision and flexibility of cell-free protein expression, together with our ability to insert nnAAs, allow us to construct our proprietary enhanced protein carrier ("eCRM") with pre-determined conjugation sites.
• Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits that are beyond the capabilities of conventional approaches.

Partnerships

• In October 2023, to complement this plan, we entered into a new commercial manufacturing agreement with Lonza to support the potential global commercialization of our PCV candidates in both the adult and pediatric populations.
• In November 2023, we entered into a manufacturing rights agreement with Sutro Biopharma, Inc ("Sutro Biopharma") to obtain control over the development and manufacture of cell-free extract, a key component of our PCV franchise.

Legal & Regulatory Risks (Item 1A, quoted)

• The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our vaccine candidates.
• We could also experience delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our vaccine candidates in lieu of using existing vaccines that have established safety and immunogenicity or efficacy profiles.
• The FDA may disagree with our regulatory plan, and we may fail to obtain regulatory approval of our vaccine candidates.
• We may seek Accelerated Approval from the FDA for our vaccine candidates and, if granted, the FDA may require us to perform post-marketing studies as a condition of approval to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoints.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:59 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt